×
Abstract GS1-01: Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS1-01

Feb 16th, 2018 - Background: Much contemporary adjuvant chemotherapy uses conventional 3-weekly scheduling. Yet, cytokinetic modelling suggests that increasing the dose density of cytotoxic therapy by shortening the intervals between courses, or by using sequential rather than concurrent treatment schedules may enhance efficacy.1 At least 15 randomised trials have directly tested this hypothesis and this meta-a...

Abstract P1-15-04: Outcome of small (≤1 cm), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-04

Sep 20th, 2018 - Background: Screening mammogram has resulted in increased diagnosis of very small breast cancers, especially less than 1 cm node negative. These small tumors have excellent prognosis with cancer-specific survival rates as high as 90% to 95%. This study evaluates outcome in different subtypes of very early breast cancer in a national population database. Method: Patients with stage I breast canc...

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS1-02

Feb 19th, 2018 - Background: Adjuvant trastuzumab (H) reduces cancer recurrence and improves survival in patients (pts) with HER2-amplified or overexpressing (IHC 3+ staining intensity) IBC. Two of the landmark trials that demonstrated the efficacy of H-based eligibility on HER2 testing performed at local site laboratories were found to contain a cohort of pts without amplification or IHC overexpression on tiss...

Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-01

Sep 21st, 2018 - BACKGROUND: The SWOG S0230/POEMS study demonstrated a 70% reduction in ovarian failure (OF) with goserelin coadministration during chemotherapy (CT) for ER-negative early breast cancer (BC; Moore H et al, NEJM 2015). Goserelin use was also associated with more pregnancies as well as favorable disease free survival (DFS) and overall survival (OS). Here we report the final analysis after 5 years ...

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS2-07

Feb 24th, 2018 - Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Vistusertib (AZD2014), a dual inhibitor of mTORC1 and mTORC2, has shown a broader range of activity in preclinical ER+ breast cancer ...

Abstract P5-22-13: Representation of surgical breast research at an interdisciplinary oncology conference
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-13

Dec 25th, 2018 - Background: The treatment of breast cancer requires an interdisciplinary approach, involving the fields of surgery, radiation oncology, medical oncology, pathology and radiology. The roles of various specialties may differ in the local versus metastatic setting. Despite the importance of collaborative care, significant disparities remain in federal funding of research among different medical sp...

Abstract GS5-01: Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-01

Feb 27th, 2018 - Background: Significant controversy exists regarding the appropriate minimum tumor-free margin width for patients undergoing breast-conserving therapy. The SSO-ASTRO guidelines recommend 'no ink on tumor' based upon a meta-analysis of 33 studies, but this had significant limitations. In order to address these concerns, a meta-analysis of all available data (using 31 of the initial studies) was ...

Abstract P5-22-21: Radioactive seed and targeted axillary dissection: A feasibility study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-21

Dec 26th, 2018 - Targeted axillary dissection (TAD) with a radioactive seed is a new and promising technique to evaluate the axillary status in post-neoadjuvant chemotherapy (NACT) node-positive breast cancer patients. This study aims to evaluate the feasibility of TAD with a radioactive seed in a Canadian setting. We conducted a retrospective observational study of a prospectively gathered database of patients...

Abstract GS4-06: Cancer risks and response to targeted therapy associated with BRCA2 variants of uncertain significance
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-06

Mar 4th, 2018 - Background: Germline genetic testing of individuals with a diagnosis of triple negative breast cancer, young age at diagnosis, or a family history of breast and/or ovarian cancer has led to the identification of many unique BRCA2 missense variants of uncertain significance (VUS). VUS in BRCA2 are predominantly missense mutations that have unclear relevance to breast, ovarian, and other cancers....

Abstract P1-15-05: Oncologists' perception of anti-estrogen therapy benefit
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-05

Sep 25th, 2018 - Background Recent publication of Suppression of Ovarian Function (SOFT) and Tamoxifen and Exemestane (TEXT) trials provides additional options for premenopausal women with hormone receptor (HR)-positive breast cancer in improving estrogen blockade - tamoxifen (T) plus ovarian function suppression (OFS) and aromatase inhibitors (AI) plus OFS. Analysis of these trials conclude that, for a premeno...

Abstract P1-15-06: Localized triple negative breast cancer in extremes of life
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-06

Sep 26th, 2018 - Background: Triple-negative breast cancer (TNBC) in young and older patients has specific features and outcomes. While in younger patients, it is characterized by being aggressive with worse survival, in advanced ages it may have a better outcome which reasons have not yet fully elucidated. Our objective was to compare clinicopathological characteristics, treatment and survival rates between ve...

Abstract GS5-07: Weight change in postmenopausal women and breast cancer risk in the women's health initiative observational study
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-07

Mar 16th, 2018 - Purpose While obesity is an established breast cancer risk factor, information about the influence of weight loss on breast cancer risk in postmenopausal women is mixed precluding generation of a strong public health message regarding potential benefits of weight loss with respect to cancer risk. Therefore, we evaluated associations between weight change and invasive breast cancer risk in postm...

Abstract P1-14-06: Selective internal radiation therapy (SIRT) with Yttrium-90 resin microspheres and FOLFOX/5FU chemotherapy in pre-treated breast cancer patients with liver metastases: A retrospe...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-06

Sep 27th, 2018 - Background: SIRT is a globally licensed technique of Radio-Embolization (RE) of hepatic tumors via intra-arterial infusion of β-particle emitting Yttrium-90 (Y-90) radio-labelled microspheres. It increases response rates and hepatic time to progression in metastatic colorectal cancer when used in combination with 5FU/Oxaliplatin (FOLFOX) chemotherapy with acceptable toxicity profile. FOLFOX giv...

Abstract BS2-1: Ocogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
http://cancerres.aacrjournals.org/content/78/4_Supplement/BS2-1

Mar 24th, 2018 - The mechanisms that produce early-disseminated cancer cells (eDCC) during early stages of breast cancer or that contribute to the development of metastasis from cancer of unknown primary (CUP) are poorly understood. Here we show that HER2+ cancer cells that are present during early stages of cancer before any overt tumors can be detected are highly efficient in systemically disseminating from p...

Abstract ES9-2: Tracking progesterone receptor actions in breast cancer progression: Jekyll and Hyde
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES9-2

Apr 1st, 2018 - Recent work on the actions for progesterone receptors (PRs) in breast cancer has raised the profile of PRs as players rather than simply markers of estrogen (E)-responsive luminal disease. Indeed, estrogen receptors (ERs) and PRs are intimate partners at the genome regulatory level rather than having a simple driver/passenger relationship. PRs alter breast cancer cell proliferation in complex w...

Abstract ES11-1: Luminal ABC: optimal use of all available options?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES11-1

Apr 5th, 2018 - Despite advanced in early detection and aggressive adjuvant endocrine therapy, recurrence and metastasis of estrogen-receptor (ER)- positive breast cancer remains a problem, with a substantial proportion of patients relapsing years after diagnosis. Biologically, these tumors are primarily of the luminal subtype, amenable to anti-estrogen strategies that can control disease growth and limit meta...

Abstract ES2-1: The pathology of high risk proliferative lesions of the breast
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES2-1

Apr 9th, 2018 - A number of breast lesions diagnosed by pathologic examination of breast tissue are known to confer an increased risk for future development of breast cancer. Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) are lesions conferring a moderately increased risk of 4-5x over baseline. Lobular carcinoma in situ (LCIS) and variants confer a markedly increased risk of 8-10x ove...

Abstract P1-11-01: Effectiveness, safety and quality of life (QoL) results from the German multicenter AVANTI study of 1st-line bevacizumab (BEV)-containing therapy in >2000 patients (pts) with ...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-11-01

Oct 3rd, 2018 - Background: In Europe, BEV is approved with either paclitaxel (PAC) or capecitabine (CAP) as 1st-line therapy for HER2-negative aBC. These regimens are being evaluated in routine oncology practice in the German AVANTI (ML22452) observational study. Methods: Eligible pts had received no prior chemotherapy (CT) for aBC and had no BEV contraindications. CT schedule, diagnostics and frequency of fo...

Abstract P1-12-02: Clinical efficacy of a humanized monoclonal antibody against the Lewis-Y antigen (Ley): Results of a phase II clinical trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-12-02

Oct 4th, 2018 - Background. The Lewis-Y (Ley) antigen is a blood group-related antigen expressed in over 70% of epithelial cancers. It is expressed in 44% of breast cancers. Objectives. The primary endpoint was to evaluate the clinical efficacy of hu3S193, a humanized monoclonal antibody against the Lewis-Y antigen, in advanced hormone positive breast cancer after failure of at least one line of endocrine ther...

Abstract P2-01-03: Improved prognostic information by serial monitoring of CTC enumeration and CTC-clusters from baseline to six months in patients with metastatic breast cancer scheduled for 1st l...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-03

May 7th, 2018 - Background: Detection and enumeration of circulating tumor cells (CTCs) allows real time monitoring of disease evolvement. In women with metastatic breast cancer (MBC), a CTC count of ≥5 CTCs is associated with decreased progression-free survival (PFS) and overall survival (OS). Serial sampling after therapy initiation has indicated that longitudinal CTC enumeration adds prognostic information,...